Covista Inc. (ATGE) Form 10-Q — Oct 29, 2026
Covista (NYSE: CVSA) reported fiscal Q1 2027 revenue of $511.5 million, up 10.7% year over year, with net income up 9.0% to $67.4 million and diluted EPS up 16.8% to $1.95. Growth was broad-based, with Walden up 14.1% on 12.8% enrollment growth and Medical and Veterinary up 10.0%. The quarter also featured aggressive capital return and deleveraging: Covista repurchased 658,088 shares at an average of $127.63 (~$84 million) with $577.8 million remaining under its $750 million authorization, and repaid $163 million of long-term debt, leaving $510 million on the Term Loan B maturing March 2033.
Key figures
- Eps
- 1.95
- Revenue
- 511534000
- Net Income
- 67427000
- Revenue Yoy
- 10.7%
- Total Assets
- 2928273000
- Cash Position
- 222223000
- Shares Outstanding
- 33255241
- Buyback q1
- 658,088 shares at avg $127.63 ($84.0M)
- Adjusted ebitda
- $131.2 million (+17.1%, 25.6% margin)
- Deferred revenue
- $365.1 million
- Operating income
- $98.0 million (19.2% margin)
- Debt repayment q1
- $163.0 million
- Revolver capacity
- $500.0 million undrawn
- Adjusted net income
- $75.8 million (+16.8% YoY)
- Adjusted diluted eps
- $2.19 (+25.1% YoY)
- Term loan b principal
- $510.0 million
- Walden enrollment growth
- 12.8%
- Adjusted operating income
- $106.6 million (+18.1%)
- Chamberlain enrollment growth
- 2.7% (July session) / 1.3% (September session)
- Remaining buyback authorization
- $577.8 million
- Medical veterinary enrollment growth
- 3.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.